10x Genomics stock

TXG · NASDAQ · USD

Compare 10x Genomics
$58.19Change from previous close: −1.54%Absolute change: −$0.91

Close · November 13, 2026

Price history

+255.90% over the period

1 year: from $16.35 (November 13, 2025) to $58.19 (November 13, 2026), +255.90%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 13, 2026$58.19
October 30, 2026$70.11
September 30, 2026$90.36
August 31, 2026$62.45
July 31, 2026$47.27
June 30, 2026$38.34
May 29, 2026$28.31
April 30, 2026$22.05
March 31, 2026$21.23
February 27, 2026$23.05
January 30, 2026$20.20
December 31, 2025$16.31
November 28, 2025$18.81
November 13, 2025$16.35

At a glance

  • The company

    Develops instruments, consumables, and software for single-cell and spatial analysis of biological systems

  • Latest results

    Quarter to September 30, 2026 · EPS $0.03 (estimate -$0.26)

TickerLandia's take on 10x Genomics

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$15.18
52-wk high$102.81

−43.40% from the 52-week high

Analysts · 17 analysts

Average target$68.14+17.10% vs. price

Buy 6 · Hold 11 · Sell 0 · Buy

TickerLandia Fingerprint: 10x Genomics

Compared with similar companies: very low earnings stability, very high price, and very high financial strength.

Financials and price compared with 31 companies in the medical devices industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

10x Genomics is pricier than similar companies

10x Genomics's Price/book: 9.13, +82% against the median of a group of 11 similar companies (5.03).

Compared with 11 similar companies

10x Genomics's metrics compared with similar companies
Metric10x GenomicsPosition in the groupBand
Operating margin-10.6%Low
ROE-8.3%Low
Debt/equity0.09Low
Price/book9.13High
Net margin-10.8%Low

Grey band: the middle half of the group; tick: the median; dot: 10x Genomics. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$151.04M

Latest quarter · Q2 2026

Net income

-$17.93M

Latest quarter · Q2 2026

Quarterly net margin

-11.9%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
$7.65B
EPS
-$0.52
Volume
2.12M
Daily trading
€194.92M
Dividend yield
0.00%

How 10x Genomics is changing

All results
  • Revenue grew 16.6% a year on average over the last 5 years

  • Operating margin rose from −31.7% to −15.6%

  • Shares outstanding up 23.3% in 5 years

Returns

10x Genomics returns

$1,000 invested in 10x Genomics 5 years ago, on November 15, 2021, would be worth $368 today: −63.17% in total, −18.13% per year. This is the price return only: dividends are excluded.

Period10x GenomicsS&P 500$1,000 becomes
1 month−18.94%−3.12%$811
6 months+176.17%+1.58%$2,762
Year to date+256.77%+10.46%$3,568
1 year+255.90%+12.23%$3,559
3 years+60.21%+71.41%$1,602
5 years−63.17%+61.48%$368

Over the last 6 months it has done better than 100% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

10x Genomics: technical analysis

10x Genomics shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 71.2% below its all-time closing high ($202.37, April 26, 2021).

Trend
No clear trend
RSI (14 sessions)
39
Between 30 and 70
vs 200-session average
+36.66%

Support and resistance

Price areas where 10x Genomics has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$67.10+15.30%2 touches, last on October 22, 2026
  2. Resistance$59.70+2.59%2 touches, last on August 31, 2026
  3. Last price$58.19
  4. Support$43.16−25.83%2 touches, last on August 7, 2026
  5. Support$35.38−39.19%2 touches, last on July 8, 2026
  6. Support$24.11−58.56%4 touches, last on May 6, 2026

Volatility and risk

Over the last year it has moved more than the S&P 500.

Beta (1 year) vs S&P 500
2.49
Volatility (60 sessions, annualised)
91.1%
Largest fall in the last year
−40.60%

Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

10x Genomics: seasonality

Average monthly price change over 8 years

+5.2%Jan−3.6%Feb−7.9%Mar−4.2%Apr+2.3%May+8.8%Jun+7.3%Jul+3.8%Aug−2.5%Sep−2.3%Oct+17.3%Nov+1.0%Dec

Over the last 8 years, the strongest month for 10x Genomics has been November: +17.31% on average, positive in 5 years out of 7. The weakest has been March: −7.87% on average, positive in 2 years out of 7.

Show chart data
MonthAverageMedianPositive years
January+5.23%+19.86%5 of 7
February−3.63%+1.47%4 of 7
March−7.87%−7.90%2 of 7
April−4.17%−5.27%3 of 7
May+2.29%+0.06%4 of 7
June+8.84%+8.79%5 of 7
July+7.28%+10.14%5 of 7
August+3.75%+4.16%4 of 7
September−2.54%−13.67%2 of 7
October−2.26%+2.62%4 of 8
November+17.31%+11.88%5 of 7
December+1.05%−5.74%2 of 7

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

10x Genomics and its competitors

Based in Pleasanton, California, and in existence since 2012, 10x Genomics supplies researchers with tools for studying biological samples at the level of individual cells and tissue locations. Its Chromium system covers single-cell analysis through microfluidic chips, reagents and kits, while the Visium platform maps gene expression across tissue slides and the Xenium Analyzer detects RNA targets in situ. Customers include academic and government institutions, biopharmaceutical companies and biotechnology firms, served across the United States, Europe, the Middle East, Africa, China and the rest of Asia Pacific.

Headquarters
Pleasanton, United States
Employees
1,178
Founded
2012
Chief executive
Serge Saxonov
10x Genomics and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
10x GenomicsTXG$7.65B-10.6%—+176.17%
InsuletPODD$10.58B18.4%24.9+2.45%
PenumbraPEN$12.65B12.1%80.8−0.52%
Zimmer Biomet HoldingsZBH$19.53B16.7%26.1+24.77%
SterisSTE$25.67B19.2%31.4+25.21%
DexComDXCM$31.08B24.0%32.8+42.27%

Same industry or related industries, similar size. Compare 10x Genomics with its competitors · Full profile